About Us
Leadership
Rajan Sah, MD, PhD
Founder & CSO,
Senseion Therapeutics
Physician-scientist trained at University of Toronto, Weill Medical College of Cornell University, and Brigham and Women’s Hospital/ Harvard University
Daniel Lerner, MD
Founder & CEO,
Senseion Therapeutics
Physician-scientist trained at UCSF with more than 15 years of experience as an executive and founder of life-science companies acquired by EV3, Covidien, and Medtronic
Drug Discovery and Development Team
Thomas Lee, PhD
VP of Drug Discovery
20 years of large pharma and biotech start-up success. Head of Chemistry at Caraway Therapeutics developing ion channel asset acquired by Merck 2024. Boehringer Ingelheim, Cyclerion, and Ironwood.
Stephen Brohawn, PhD
Structural Biologist
Associate Professor, Dept of Molecular & Cell Biology at UC Berkeley.
Expert in structural biology of ion channels. Multiple high-resolution cryo-EM structures of Senseion compounds bound to LRRC8 channels.
Andy Jennings, PhD
Head of Computation and Structural Chemistry
35 years as researcher and executive in large pharma and biotech. Discovery/ development of drugs worth in excess of $1 B. Nitrase, ShouTi, (Structure Therapeutics), Takeda, GlaxoSmithKline, and Beechams
Scientific Advisors
David Clapham,
MD, PhD
National Academy of Sciences
Internationally recognized thought leader on ion channels
Former Vice President & Chief Scientific Officer, Howard Hughes Medical Institute
Professor Emeritus of CV Research at Boston Children’s Hospital
Co-founder of Hydra
Marc Bonaca, MD, MPH
Internationally recognized leader of cardiometabolic trials
Executive Director Clinical Research, Director of Vascular Research, University of Colorado School of Medicine
Designed/Conducted multiple Phase II/III studies for breakthrough cardiometabolic drugs including SGLT2i and anticoagulants.